Developer docs
API playgroundTry for free, no card

Search company profiles

SG Austria

Full company profile

uuid000i1is

Namestring
SG Austria
Legal namestring
Austrianova Singapore
Websiteurl
sgaustria.com
Company typeenum
Private
Founded yearint
2007
Descriptiontext

SG Austria, operating under the brand Austrianova, is a Singapore-based B2B biotechnology company specializing in cell encapsulation technology. Its core platforms are two proprietary micro-encapsulation technologies — Cell-in-a-Box®, which builds a porous capsule around living human and animal cells to enable immuno-protection, free diffusion of nutrients and waste, and storage/transport; and Bac-in-a-Box®, which applies the same encapsulation principle to probiotic bacteria and yeast for stomach-acid protection and ambient storage. The company monetizes these platforms through a mix of technology licensing and partnership arrangements, plus professional-service revenue streams including US-FDA compliant GMP cell banking (GMP4Cells), standardized allogenic stem cell manufacturing, and full-cycle cell line development (sourcing, plasmid design, clone generation, in vitro/in vivo assay testing). Its customer base is concentrated in biotechnology and pharmaceutical enterprises requiring cell-biology services, cell-encapsulation IP, and GMP-compliant manufacturing inputs for therapeutic development programs.

Austrianova's go-to-market is enterprise-focused: it pursues direct B2B engagement with biotech and pharmaceutical counterparties, supplemented by scientific publications and press release distribution to build credibility, and increasingly by formal joint ventures and co-development partnerships. Recent strategic activity underscores a deliberate shift from pure service provider toward asset-light therapeutic co-development — most visibly through the September 2025 establishment of Klothonova, a 50/50 joint venture with publicly traded Avaí Bio (OTCQB: AVAI) to develop cell-based anti-aging therapies targeting α-Klotho protein, and through a Cell-in-a-Box® partnership with Avant Technologies for beta cell replacement in type 1 and insulin-dependent type 2 diabetes. The company completed a preferred equity financing in 2025 led by Checkmate Capital Group, whose CEO joined the board in April 2026, and completed a GMP Master Cell Bank for the Klothonova program in May 2026. With 1-10 employees, ISO 9001:2015 certification, and a broad portfolio of registered trademarks and named therapeutic applications spanning antibodies, cytokines, exosomes, cancer, metabolic disease, probiotics, agriculture, bioremediation, and cosmetics, the company operates as a lean, IP-centric platform licensing and specialty services business.

Leadership is held by Brian Salmons (CEO & President), Walter Gunzburg (Co-Founder), Louise Bussieres (CFO), and John Dangerfield (COO). The legal entity, Austrianova Singapore Pte. Ltd., is a Singapore private limited company with no public listing; ownership beyond the Checkmate Capital Group preferred equity stake and the 50/50 Klothonova JV interest is not publicly disclosed.

Short descriptiontext

SG Austria (Austrianova) is a Singapore-based B2B biotechnology company that licenses proprietary Cell-in-a-Box® and Bac-in-a-Box® micro-encapsulation technologies and provides US-FDA compliant GMP cell banking, allogenic stem cell manufacturing, and cell line development services to biotechnology and pharmaceutical clients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSingapore, Singapore
HQ citystring
Singapore
HQ countrystring
Singapore
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell encapsulation services, GMP cell banking, stem cell manufacturing, biotechnology services, cell line development
Industry4 codes
PRIMARYHLAIACAD
Endocrinology & Metabolic Specialty Pharmaceuticals
SECONDARYHLAGAKAI
Clinical Quality Assurance (GCP QA, TMF/QMS oversight)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
SECONDARYHLAAAFAD
Engineered Microbial Therapeutics (synthetic biology, gene circuits)
SECONDARYAFADAGAG
Probiotic/Direct-Fed Microbial (DFM) Premixes
Agriculture & Food Production/Animal Feed Manufacturing/Feed Premixes & Concentrates (Vitamins, Minerals, Additives)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Cell Encapsulation Biotechnology Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1GMP Cell Banking Services
TypeProfessional Services
Description

B2B revenue from providing GMP-compliant cell banking and processing services for biotech and pharmaceutical companies requiring FDA-compliant cell banks.

austrianova.com
2Cell Encapsulation Technology Licensing
TypeLicensing Royalties
Description

Technology licensing and partnership revenue from Cell-in-a-Box and Bac-in-a-Box encapsulation technologies used by partner companies.

austrianova.com
3Stem Cell Manufacturing Services
TypeProfessional Services
Description

Standardised allogenic cell therapy manufacturing services for treating various diseases including Graft versus Host disease and cancers.

austrianova.com
4Cell Line Development Services
TypeProfessional Services
Description

R&D services including cell sourcing, plasmid design, clone generation and characterization, and in vitro/in vivo assay testing.

austrianova.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1Cell-in-a-Box®
Description

Protective micro-encapsulation technology for living cells providing immuno-protection and localization in patients

austrianova.com
+2 more records
Core offering1 text field

SG Austria (operating as Austrianova) is a Singapore-based biotechnology company that develops and applies proprietary cell encapsulation technologies—Cell-in-a-Box® for living human and animal cells and Bac-in-a-Box® for probiotic bacteria and yeast. It also delivers related B2B cell biology services including US-FDA compliant GMP cell banking (GMP4Cells), allogeneic stem cell manufacturing, and complete cell line development R&D services for biotech and pharmaceutical customers.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Austrianova (SG Austria) is a biotechnology company offering a portfolio of cell encapsulation and manufacturing technologies. The core offerings consist of two proprietary platform technologies: Cell-in-a-Box® for micro-encapsulation of living human and animal cells providing immuno-protection and localization, and Bac-in-a-Box® for encapsulation of probiotic bacteria and yeast providing stomach acid protection and ambient storage. These platforms are supported by non-encapsulated services including GMP Cell Banking (GMP4Cells) for FDA-compliant cell banking, Stem Cell Manufacturing for allogenic cell therapy, and Cell Line Development for complete R&D services. The technologies serve diverse applications across antibody and cytokine production, metabolic diseases, cancer therapy, agriculture, probiotics, and bio-remediation.

Product and service5 records
1Cell-in-a-Box®
CategoryCell Encapsulation Technology
Description

Proprietary protective micro-encapsulation technology that protects, isolates, stores, and transports living human and animal cells, providing immuno-protection and localization in patients. The porous capsule allows free diffusion of nutrients in, waste products out, and biological molecules synthesized by the cells to escape. Designed for biotech and pharmaceutical customers developing cell-based therapies.

2Bac-in-a-Box®
CategoryCell Encapsulation Technology
Description

Proprietary encapsulation technology for probiotic bacteria and yeast that provides stomach acid protection and ambient storage. The porous capsule protects bacteria and yeast while allowing nutrient diffusion, growth within capsules, and subsequent release. Targeted at human probiotics, farming, agriculture, aquaculture, cosmetics, and bio-remediation applications.

3GMP Cell Banking (GMP4Cells)
CategoryGMP Manufacturing Services
Description

Full GMP (Good Manufacturing Practice) service for living eukaryotic human and animal cells, including preparation of cell banks and processing of cell lines in a US-FDA compliant manner for adherent or non-adherent qualified cells. For biotech and pharmaceutical companies requiring FDA-compliant cell banks.

4Stem Cell Manufacturing
CategoryCell Therapy Manufacturing
Description

Standardized allogeneic cell therapy manufacturing service that can be used for all patients without requiring use of the patient's own cells. Applicable for treating Graft versus Host disease, various types of cancer, and infectious diseases. Targeted at biotech and pharmaceutical companies developing off-the-shelf cell therapies.

5Cell Line Development
CategoryCell Biology R&D Services
Description

Complete cell R&D service from sourcing cells and designing appropriate plasmids to generating and characterising clones, with testing of cell clones in various in vitro or in vivo assays through an extensive network of trusted partners. For biotech and pharmaceutical customers needing custom cell line development.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-01
Description

Joint venture Klothonova established in September 2025, equally owned by Avaí Bio and Austrianova's affiliate SG Austria Pte. Ltd. Focused on restoring declining α-Klotho levels associated with aging and age-related conditions through cell-based therapy. Avaí Bio is an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership for Cell-in-a-Box microencapsulation technology. Avant Technologies is evaluating advanced cells for potential application in diabetes therapy, specifically beta cell replacement for type 1 and insulin-dependent type 2 diabetes patients. The technology offers immunosuppression-free protection for transplanted insulin-producing cells.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1BioGaia
TypeEmerging player
Description

Swedish probiotics company developing probiotic products with protective delivery technologies for gut health applications. Comparable as a focused probiotics player whose product strategy could leverage encapsulation technology similar to Bac-in-a-Box®.

TypeBroad incumbent
Description

Global CDMO (now under Novo Holdings ownership) offering cell therapy and biologics manufacturing services including cell banking capabilities. Comparable as a broad incumbent competing for cell therapy and GMP manufacturing contracts.

TypeBroad incumbent
Description

Global CDMO providing mammalian cell culture, microbial fermentation, and cell therapy manufacturing services. Comparable as a broad incumbent offering GMP-compliant biologics and cell therapy manufacturing that overlaps with SG Austria's GMP4Cells service offering.

TypeBroad incumbent
Description

Global CDMO leader offering cell and gene therapy manufacturing services including GMP cell banking. Comparable as a broad incumbent providing GMP-compliant cell therapy manufacturing infrastructure that competes for similar biotech and pharma customers.

TypeEmerging player
Description

Major biotech developing VX-880 and VX-264 (encapsulated stem cell-derived islet) cell therapies for type 1 diabetes. Represents both an overlapping therapeutic indication (T1D cell therapy) and a competitive alternative encapsulation approach to SG Austria's beta cell replacement platform.

TypeBroad incumbent
Description

Global biosolutions leader (formed via Novozymes-Chr. Hansen merger) with extensive microbial encapsulation capabilities for probiotics, agriculture, and industrial biotechnology. Comparable as a broad incumbent in microbial encapsulation technologies overlapping with SG Austria's Bac-in-a-Box® applications.

TypeDirect peer
Description

Private biotech developing encapsulated stem cell-derived islet therapies for type 1 diabetes. Directly comparable technology and indication overlap with SG Austria's Cell-in-a-Box® diabetes applications through Avant Technologies.

TypeDirect peer
Description

ASX-listed cell encapsulation company developing encapsulated porcine cell therapies for Parkinson's disease and diabetes. Directly comparable as a cell encapsulation platform company focused on therapeutic cell delivery and immuno-isolation.

TypeDirect peer
Description

Israeli biotech developing a microencapsulation platform (ESCellarate™) for pancreatic islet cell transplantation in diabetes. Comparable as a microencapsulation-based cell therapy company targeting insulin-dependent diabetes.

TypeEmerging player
Description

Emerging cell therapy manufacturing automation company offering integrated cell therapy GMP production platforms. Comparable as a technology-enabled cell therapy manufacturing services provider targeting the same biotech customer base as SG Austria's GMP4Cells service.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SG Austria

Cell Encapsulation Biotechnology Servicessgaustria.com

SG Austria (Austrianova) is a Singapore-based B2B biotechnology company that licenses proprietary Cell-in-a-Box® and Bac-in-a-Box® micro-encapsulation technologies and provides US-FDA compliant GMP cell banking, allogenic stem cell manufacturing, and cell line development services to biotechnology and pharmaceutical clients.

What SG Austria does

SG Austria, operating under the brand Austrianova, is a Singapore-based B2B biotechnology company specializing in cell encapsulation technology. Its core platforms are two proprietary micro-encapsulation technologies — Cell-in-a-Box®, which builds a porous capsule around living human and animal cells to enable immuno-protection, free diffusion of nutrients and waste, and storage/transport; and Bac-in-a-Box®, which applies the same encapsulation principle to probiotic bacteria and yeast for stomach-acid protection and ambient storage. The company monetizes these platforms through a mix of technology licensing and partnership arrangements, plus professional-service revenue streams including US-FDA compliant GMP cell banking (GMP4Cells), standardized allogenic stem cell manufacturing, and full-cycle cell line development (sourcing, plasmid design, clone generation, in vitro/in vivo assay testing). Its customer base is concentrated in biotechnology and pharmaceutical enterprises requiring cell-biology services, cell-encapsulation IP, and GMP-compliant manufacturing inputs for therapeutic development programs.

Austrianova's go-to-market is enterprise-focused: it pursues direct B2B engagement with biotech and pharmaceutical counterparties, supplemented by scientific publications and press release distribution to build credibility, and increasingly by formal joint ventures and co-development partnerships. Recent strategic activity underscores a deliberate shift from pure service provider toward asset-light therapeutic co-development — most visibly through the September 2025 establishment of Klothonova, a 50/50 joint venture with publicly traded Avaí Bio (OTCQB: AVAI) to develop cell-based anti-aging therapies targeting α-Klotho protein, and through a Cell-in-a-Box® partnership with Avant Technologies for beta cell replacement in type 1 and insulin-dependent type 2 diabetes. The company completed a preferred equity financing in 2025 led by Checkmate Capital Group, whose CEO joined the board in April 2026, and completed a GMP Master Cell Bank for the Klothonova program in May 2026. With 1-10 employees, ISO 9001:2015 certification, and a broad portfolio of registered trademarks and named therapeutic applications spanning antibodies, cytokines, exosomes, cancer, metabolic disease, probiotics, agriculture, bioremediation, and cosmetics, the company operates as a lean, IP-centric platform licensing and specialty services business.

Leadership is held by Brian Salmons (CEO & President), Walter Gunzburg (Co-Founder), Louise Bussieres (CFO), and John Dangerfield (COO). The legal entity, Austrianova Singapore Pte. Ltd., is a Singapore private limited company with no public listing; ownership beyond the Checkmate Capital Group preferred equity stake and the 50/50 Klothonova JV interest is not publicly disclosed.

SG Austria firmographics

Firmographics
Name
SG Austria
Legal name
Austrianova Singapore
Website
https://sgaustria.com
Company type
Private
Founded year
2007
Operating status
Operating
Headcount range
1–10 employees
Short description
SG Austria (Austrianova) is a Singapore-based B2B biotechnology company that licenses proprietary Cell-in-a-Box® and Bac-in-a-Box® micro-encapsulation technologies and provides US-FDA compliant GMP cell banking, allogenic stem cell manufacturing, and cell line development services to biotechnology and pharmaceutical clients.
Ownership category
akta.pro rank

SG Austria industry classification

Industry
Product category
Cell Encapsulation Biotechnology Services
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAD
Endocrinology & Metabolic Specialty Pharmaceuticals
SECONDARYHLAGAKAI
Clinical Quality Assurance (GCP QA, TMF/QMS oversight)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
SECONDARYHLAAAFAD
Engineered Microbial Therapeutics (synthetic biology, gene circuits)
SECONDARYAFADAGAG
Probiotic/Direct-Fed Microbial (DFM) Premixes
Agriculture & Food Production/Animal Feed Manufacturing/Feed Premixes & Concentrates (Vitamins, Minerals, Additives)

Keywords

  • Cell encapsulation services
  • GMP cell banking
  • Stem cell manufacturing
  • Biotechnology services
  • Cell line development

Where SG Austria is headquartered

Location

Headquarters

HQ city
Singapore
HQ country
Singapore
HQ region
Asia

Offices1 record

Markets served

SG Austria business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

  1. GMP Cell Banking Services: B2B revenue from providing GMP-compliant cell banking and processing services for biotech and pharmaceutical companies requiring FDA-compliant cell banks.
  2. Cell Encapsulation Technology Licensing: Technology licensing and partnership revenue from Cell-in-a-Box and Bac-in-a-Box encapsulation technologies used by partner companies.
  3. Stem Cell Manufacturing Services: Standardised allogenic cell therapy manufacturing services for treating various diseases including Graft versus Host disease and cancers.
  4. Cell Line Development Services: R&D services including cell sourcing, plasmid design, clone generation and characterization, and in vitro/in vivo assay testing.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

SG Austria product offering

Product offering

Core offering

SG Austria (operating as Austrianova) is a Singapore-based biotechnology company that develops and applies proprietary cell encapsulation technologies—Cell-in-a-Box® for living human and animal cells and Bac-in-a-Box® for probiotic bacteria and yeast. It also delivers related B2B cell biology services including US-FDA compliant GMP cell banking (GMP4Cells), allogeneic stem cell manufacturing, and complete cell line development R&D services for biotech and pharmaceutical customers.

Product overview

Austrianova (SG Austria) is a biotechnology company offering a portfolio of cell encapsulation and manufacturing technologies. The core offerings consist of two proprietary platform technologies: Cell-in-a-Box® for micro-encapsulation of living human and animal cells providing immuno-protection and localization, and Bac-in-a-Box® for encapsulation of probiotic bacteria and yeast providing stomach acid protection and ambient storage. These platforms are supported by non-encapsulated services including GMP Cell Banking (GMP4Cells) for FDA-compliant cell banking, Stem Cell Manufacturing for allogenic cell therapy, and Cell Line Development for complete R&D services. The technologies serve diverse applications across antibody and cytokine production, metabolic diseases, cancer therapy, agriculture, probiotics, and bio-remediation.

Differentiator

Problem solved

Functional benefit

Brands

  • Cell-in-a-Box®: Protective micro-encapsulation technology for living cells providing immuno-protection and localization in patients
  • Bac-in-a-Box®
  • GMP4Cells

Products and services

  • Cell-in-a-Box® Proprietary protective micro-encapsulation technology that protects, isolates, stores, and transports living human and animal cells, providing immuno-protection and localization in patients. The porous capsule allows free diffusion of nutrients in, waste products out, and biological molecules synthesized by the cells to escape. Designed for biotech and pharmaceutical customers developing cell-based therapies.
  • Bac-in-a-Box® Proprietary encapsulation technology for probiotic bacteria and yeast that provides stomach acid protection and ambient storage. The porous capsule protects bacteria and yeast while allowing nutrient diffusion, growth within capsules, and subsequent release. Targeted at human probiotics, farming, agriculture, aquaculture, cosmetics, and bio-remediation applications.
  • GMP Cell Banking (GMP4Cells) Full GMP (Good Manufacturing Practice) service for living eukaryotic human and animal cells, including preparation of cell banks and processing of cell lines in a US-FDA compliant manner for adherent or non-adherent qualified cells. For biotech and pharmaceutical companies requiring FDA-compliant cell banks.
  • Stem Cell Manufacturing Standardized allogeneic cell therapy manufacturing service that can be used for all patients without requiring use of the patient's own cells. Applicable for treating Graft versus Host disease, various types of cancer, and infectious diseases. Targeted at biotech and pharmaceutical companies developing off-the-shelf cell therapies.
  • Cell Line Development Complete cell R&D service from sourcing cells and designing appropriate plasmids to generating and characterising clones, with testing of cell clones in various in vitro or in vivo assays through an extensive network of trusted partners. For biotech and pharmaceutical customers needing custom cell line development.

Companies that use SG Austria

Customer profile

Named customers2 records

Segments1 record

Ideal customer profiles1 record

SG Austria technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

SG Austria partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Avaí BiocoreStrategic or Co-development Partner · 1 September 2025Joint venture Klothonova established in September 2025, equally owned by Avaí Bio and Austrianova's affiliate SG Austria Pte. Ltd. Focused on restoring declining α-Klotho levels associated with aging and age-related conditions through cell-based therapy. Avaí Bio is an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging.
  • Avant TechnologiescoreStrategic or Co-development PartnerPartnership for Cell-in-a-Box microencapsulation technology. Avant Technologies is evaluating advanced cells for potential application in diabetes therapy, specifically beta cell replacement for type 1 and insulin-dependent type 2 diabetes patients. The technology offers immunosuppression-free protection for transplanted insulin-producing cells.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

SG Austria competitors and assessment

Company assessment

Emerging players

  • BioGaia: Swedish probiotics company developing probiotic products with protective delivery technologies for gut health applications. Comparable as a focused probiotics player whose product strategy could leverage encapsulation technology similar to Bac-in-a-Box®.
  • Vertex Pharmaceuticals: Major biotech developing VX-880 and VX-264 (encapsulated stem cell-derived islet) cell therapies for type 1 diabetes. Represents both an overlapping therapeutic indication (T1D cell therapy) and a competitive alternative encapsulation approach to SG Austria's beta cell replacement platform.
  • Cellares: Emerging cell therapy manufacturing automation company offering integrated cell therapy GMP production platforms. Comparable as a technology-enabled cell therapy manufacturing services provider targeting the same biotech customer base as SG Austria's GMP4Cells service.

Broad incumbents

  • Catalent: Global CDMO (now under Novo Holdings ownership) offering cell therapy and biologics manufacturing services including cell banking capabilities. Comparable as a broad incumbent competing for cell therapy and GMP manufacturing contracts.
  • AGC Biologics: Global CDMO providing mammalian cell culture, microbial fermentation, and cell therapy manufacturing services. Comparable as a broad incumbent offering GMP-compliant biologics and cell therapy manufacturing that overlaps with SG Austria's GMP4Cells service offering.
  • Lonza Group: Global CDMO leader offering cell and gene therapy manufacturing services including GMP cell banking. Comparable as a broad incumbent providing GMP-compliant cell therapy manufacturing infrastructure that competes for similar biotech and pharma customers.
  • Novonesis (formerly Novozymes): Global biosolutions leader (formed via Novozymes-Chr. Hansen merger) with extensive microbial encapsulation capabilities for probiotics, agriculture, and industrial biotechnology. Comparable as a broad incumbent in microbial encapsulation technologies overlapping with SG Austria's Bac-in-a-Box® applications.

Direct peers

  • Seraxis: Private biotech developing encapsulated stem cell-derived islet therapies for type 1 diabetes. Directly comparable technology and indication overlap with SG Austria's Cell-in-a-Box® diabetes applications through Avant Technologies.
  • Living Cell Technologies: ASX-listed cell encapsulation company developing encapsulated porcine cell therapies for Parkinson's disease and diabetes. Directly comparable as a cell encapsulation platform company focused on therapeutic cell delivery and immuno-isolation.
  • Betalin Therapeutics: Israeli biotech developing a microencapsulation platform (ESCellarate™) for pancreatic islet cell transplantation in diabetes. Comparable as a microencapsulation-based cell therapy company targeting insulin-dependent diabetes.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

SG Austria social profiles

Digital presence

SG Austria compliance and trust

Trust signal

Compliance2 records

SG Austria financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SG Austria leadership team

Management profile

Number of profiles

Profiles5 records

SG Austria subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

SG Austria funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SG Austria M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SG Austria

What does SG Austria do?

SG Austria (operating as Austrianova) is a Singapore-based biotechnology company that develops and applies proprietary cell encapsulation technologies—Cell-in-a-Box® for living human and animal cells and Bac-in-a-Box® for probiotic bacteria and yeast. It also delivers related B2B cell biology services including US-FDA compliant GMP cell banking (GMP4Cells), allogeneic stem cell manufacturing, and complete cell line development R&D services for biotech and pharmaceutical customers.

Is SG Austria a public or private company?

SG Austria is a private company. It is classified as venture growth investor backed and is currently operating.

When was SG Austria founded?

SG Austria was founded in 2007. It employs 1 to 10 people.

Where is SG Austria based?

SG Austria is headquartered in Singapore, Singapore, in the Asia region.

How does SG Austria make money?

Four revenue lines are on record. GMP Cell Banking Services are the primary driver. The others are cell Encapsulation Technology Licensing, stem Cell Manufacturing Services and cell Line Development Services.

Who are SG Austria's main competitors?

Emerging players on record are BioGaia, Vertex Pharmaceuticals and Cellares. Broad incumbents are Catalent, AGC Biologics, Lonza Group and Novonesis (formerly Novozymes). Direct peers are Seraxis, Living Cell Technologies and Betalin Therapeutics.

Does SG Austria have an API?

No public API is recorded for SG Austria.

What industry is SG Austria in?

SG Austria's product category is Cell Encapsulation Biotechnology Services. Its primary akta.pro industry code is HLAIACAD, Endocrinology & Metabolic Specialty Pharmaceuticals, with a secondary code of HLAGAKAI, Clinical Quality Assurance (GCP QA, TMF/QMS oversight). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
NewswireCell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative MarketsCell-based therapies are advancing in anti-aging and neurodegenerative markets, with the global cell therapy market projected to grow from $4.7 billion in 2023 to over $20 billion by 2030. Senolytics and anti-aging pharmaceuticals could reach $6.39 billion by 2030, while neurodegenerative treatments may expand from $58.4 billion in 2025 to $85 billion by 2032.openPR.comSG Austria/Austrianova Announces the Appointment of C. Thomas Paschall, to the Board following the Successful closing of 2025 Financing Round Led by Checkmate Capital GroupSG Austria/Austrianova appointed C. Thomas Paschall, CEO and Founder of Checkmate Capital, to its Board as of April 4th, 2026, following a successful preferred equity financing round led by Checkmate Capital Group in 2025. The financing enabled critical capital expenditures and the pursuit of joint ventures and industry partnerships that have increased the company's value heading into 2026. Paschall brings extensive biotech investment experience and had been advising the company prior to his board appointment.openPR.comSG Austria/Austrianova announces the appointment of C. Thomas Paschall to the Board, following the previous closing of the 2025 Financing Round led by Checkmate Capital GroupSG Austria/Austrianova announced the appointment of C. Thomas Paschall, CEO and Founder of Checkmate Capital Group, to its Board of Directors as of April 4th, 2026. The appointment follows the successful closing of a preferred equity financing round led by Checkmate Capital Group in 2025, which enabled critical capital expenditures and further pursuit of joint ventures and industry partnerships. The company stated that Paschall's extensive biotech investment experience and commercial acumen will enhance business capabilities as Austrianova expands its manufacturing and upscaling services.NewswireAvant Technologies Highlights the Critical Role of Cell Encapsulation Technology in Revolutionizing Diabetes TreatmentAvant Technologies and SGAustria Pte. Ltd. have formed a joint venture called Insulinova, Inc. to develop and conduct clinical trials for a cell-based diabetes treatment using SGAustria's Cell-in-a-Box® encapsulation technology. The technology protects genetically modified insulin-producing cells from immune rejection without requiring immunosuppression, potentially offering a functional cure for type 1 diabetes and reducing dependency on external insulin for type 2 patients. The partnership addresses a significant unmet need, with the International Diabetes Federation projecting 853 million people will live with diabetes globally by 2050.Business Wire BlogAvant Technologies Signs Joint Venture to Advance Cell-Based Diabetes TreatmentAvant Technologies Inc., a Nevada-based technology company, has formed a joint venture with SGAustria Pte. Ltd., a Singapore-based biotechnology company, to develop a cell-based diabetes treatment using stem cell differentiation and encapsulation technologies. The partnership will create Insulinova, Inc., a U.S. company, to facilitate clinical trials, with SGAustria contributing its clinically proven cell-encapsulation platform backed by over 50 peer-reviewed publications and Avant providing initial funding over eight months. The joint venture aims to deliver treatments for type 1 and some insulin-dependent type 2 diabetes patients, pursuing a potential Phase 1 clinical trial in the United States or equivalent territory.GlobeNewswireAustrianova Secures Investment from Checkmate CapitalCheckmate Capital Group made a preferred equity investment in SG Austria, parent of Austrianova, a cell encapsulation biotech. Proceeds will expand its GMP, ISO9001:2015-certified facility in Thailand. The investment aims to support commercial scaleup across biopharmaceutical, agritech, and food science industries.GlobeNewswirePharmaCyte Biotech Board of Directors Announces Business Review Committee to Evaluate Opportunities to Optimize Shareholder ValuePharmaCyte Biotech's Board formed a Business Review Committee to evaluate opportunities to optimize shareholder value, and CEO Kenneth L. Waggoner stepped down effective October 6, 2022, with Joshua N. Silverman appointed interim CEO. The committee will review the FDA clinical hold on the Cell-in-a-Box IND and the company's relationship with SG Austria, while spending on programs has been curtailed.GlobeNewswireNuvilex (NVLX) Acquires 14.5% Equity Interest in AustrianovaNuvilex received a 14.5% equity interest in Austrianova from SGAustria Pte. Ltd., fulfilling an obligation under an asset purchase agreement. The deal grants Nuvilex exclusive worldwide rights to use Austrianova's Cell-in-a-Box technology for cancer and diabetes treatments. Nuvilex plans to advance late-phase clinical trials in advanced pancreatic cancer.GlobeNewswireNuvilex Advances Company Toward Future Clinical Treatments Through Successful Acquisition of Exclusive Worldwide Rights to Live-Cell Encapsulation Technology for DiabetesNuvilex acquired exclusive worldwide rights to a cellulose-based live-cell encapsulation technology for diabetes treatment from SG Austria Pte. Ltd. The company raised $1.5 million in restricted stock at $0.15 per share, using $1 million for the acquisition and the remainder for Phase 3 pancreatic cancer trials. Proof-of-principle studies showed encapsulated cells normalized blood glucose in diabetic animals.GlobeNewswireNuvilex Completes Acquisition of Exclusive Worldwide Rights to Live-Cell Encapsulation Technology for DiabetesNuvilex acquired exclusive worldwide rights to a cellulose-based live-cell encapsulation technology for diabetes treatment from SG Austria Pte. Ltd. The company raised $1.5 million in restricted stock, using $1 million for the acquisition and $0.5 million for Phase 3 pancreatic cancer trials. Proof-of-principle studies showed encapsulated cells normalized blood glucose in diabetic animals.